WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-02·Latest →

Amgen (AMGN) Stock Analysis

HOLD

AMGN Equity Research — HOLD — June 2026

← ABTBMY →

Rating date

Jun 2, 2026

69 days ago

Desk view

HOLD

5D move

+5.32%

Neutral (HOLD unscored)

Peer rank

32p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · AMGN

*May 15, 2026, includes a $2.52 dividend. Prices are unadjusted for dividends.

Desk rating

HOLD

Tactical UW · 12M HOLD

Horizon

Tactical UNDERWEIGHT · 12M HOLD

Confidence

Low

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

HOLD

Catalysts

  • EU approval for Imdylltra is the standout positive catalyst — a clinically meaningful label expansion backed by a 40% survival benefit.
  • The stock's 13% decline over three months suggests the market has been pricing in LOE/pricing concerns more than recent regulatory wins.
  • The narrative is split between "structural headwinds" (mature portfolio erosion) and "growth pipeline optionality" (new drugs, biosimilars).

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

AMGN Research Note

Full desk note for Jun 2, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

31 min read

WebserviceX · Agentic Research Desk

AMGN Equity Research Note

Published Jun 2, 2026 · Desk view HOLD · Generated 2026-06-03T04:33:19Z · Maintained by Walter Vijayakumar · Methodology · Track record

AMGN Stock Rating Summary

AMGN bias

HOLD

Horizon

Tactical UNDERWEIGHT · 12M HOLD

AMGN key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

AMGN catalyst watch

EU approval for Imdylltra is the standout positive catalyst — a clinically meaningful label expansion backed by a 40% survival benefit.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Low

How the call aged · 5D

+5.32%Neutral (HOLD unscored)Peer 32p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-09T07:21:29.179871+00:00.

5D move

+5.32%

2026-06-02 → 2026-06-08

Outcome

Neutral (HOLD unscored)

5D trend

-2.29%

Vol (20D ann.)

+18.61%

vs SPY: -3.48%

Close 328.26 → — (USD, vendor closes)

Batch scorecard · 2026-06-02 · AMGN

Publish QC

passed
Expand

Pipeline fingerprint 781c0b04aa680fac

No QC issues recorded.